Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma.
Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve. This study was carried out to investigate the effects of alendronate in patients with hypercalcemia due to bone metastasis of hepatocellular carcinoma (HCC). Two patients were evaluated. Their corrected serum calcium and alpha-fetoprotein (AFP) levels and their computed tomography (CT), bone scintigraphy and magnetic resonance imaging (MRI) findings were evaluated before and during alendronate treatment. After treatment, not only the corrected serum calcium levels but also AFP levels and bone pain decreased; in addition, the regression of the metastatic focus was noted in the MRI analysis. These tumor inhibitory effects of alendronate have not been reported in HCC before; and alendronate might serve to prevent bone metastases in patients with HCC. In conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.
Ohnishi
T
T
First Department of Surgery, University of Tokushima, School of Medicine, Japan. tohnishi@gan2.res.ncc.go.jp
Takeda
E
E
Yogita
S
S
Miyake
H
H
Kinoshita
T
T
Terashima
Y
Y
Matsumoto
T
T
Tashiro
S
S
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000556:secondary*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery; D008297:Male
D019386:Alendronate